Protalix BioTherapeutics
PLX
About: Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
Employees: 213
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
553% more call options, than puts
Call options by funds: $379K | Put options by funds: $58K
375% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 4
4.47% more ownership
Funds ownership: 10.49% [Q1] → 14.96% (+4.47%) [Q2]
0% more funds holding
Funds holding: 63 [Q1] → 63 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 30
16% less capital invested
Capital invested by funds: $21M [Q1] → $17.6M (-$3.33M) [Q2]
Financial journalist opinion
Based on 3 articles about PLX published over the past 30 days
